Serum valproate levels with oral contraceptive use.
Herzog
Andrew G
AG
Harvard Neuroendocrine Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. aherzog@bidmc.harvard.edu
Farina
Erin L
EL
Blum
Andrew S
AS
D000328:Adult; D000927:Anticonvulsants / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015897:Comorbidity; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004338:Drug Combinations; D004347:Drug Interactions; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D004997:Ethinyl Estradiol / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005040:Ethynodiol Diacetate / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy / Q000453:epidemiology; D008599:Menstruation Disturbances / Q000188:drug therapy / Q000453:epidemiology; D014635:Valproic Acid / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000927:Anticonvulsants; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D014635:Valproic Acid; D005040:Ethynodiol Diacetate; C021601:SC-11800 EE